Revvity, Inc. (NYSE: RVTY) has announced a strategic collaboration with Profluent to launch a new generation of AI-enhanced adenine base editing systems built on Revvity’s proprietary Pin-point™ platform. The partnership combines Profluent’s AI-engineered deaminases with Revvity’s modular base editing technology to create a more precise, efficient, and customizable toolkit for gene therapy development. The updated Pin-point system enables single-nucleotide precision in base editing, minimizing unwanted bystander edits and reducing off-target effects. This level of control is critical for therapeutic applications where safety and reproducibility are essential. The platform’s design allows for ultra-low delivery of deaminase enzymes while maintaining high editing efficiency—offering a significant advantage for clinical translation. Dr. Michelle Fraser, Head of Cell and Gene Therapy at Revvity, highlighted the transformative potential of the collaboration. She noted that traditional adenine base editors have been constrained by limitations in protein engineering and licensing. With Profluent’s AI-designed enzymes, scientists can now access novel, open-access components that enable rapid iteration and tailored solutions for editing disease-relevant genetic mutations with greater accuracy and fewer unintended changes. Unlike conventional base editors derived from naturally occurring enzymes, Profluent’s approach uses artificial intelligence to design proteins from scratch. This de novo design process allows for greater functional innovation, faster development cycles, and improved therapeutic performance. The collaboration builds on Revvity’s prior success in integrating Profluent’s open-access OpenCRISPR™ nuclease into the Pin-point platform, a breakthrough previously published in Nature. The new AI-enhanced base editing systems will be offered through bundled licensing by Revvity, expanding the range of treatable genetic mutations and accelerating adoption by biopharma and gene therapy developers. The goal is to democratize access to next-generation editing tools, helping bring life-changing therapies to patients faster. Revvity will showcase the new system, along with other advancements in gene editing and health science, at the ESGCT 2025 Annual Congress in Seville, Spain, from October 7 to 10. Revvity, a leader in health science solutions, serves pharmaceutical and biotech companies, diagnostic labs, academic institutions, and government agencies across more than 160 countries. With over $2.7 billion in revenue in 2024 and approximately 11,000 employees, Revvity is a component of the S&P 500 and is committed to driving innovation from discovery to cure. Profluent, founded in 2022 and based in Emeryville, California, is an AI-first company pioneering de novo protein design. Backed by top-tier investors including Spark Capital, Insight Partners, and Air Street Capital, Profluent is focused on creating new biological solutions to transform medicine, agriculture, and beyond. More information is available at profluent.bio.